By Counterforce Health Team in Zolgensma (onasemnogene abeparvovec) —

If Zolgensma Isn't Approved by Blue Cross Blue Shield in North Carolina: Spinraza, Evrysdi & Exception Strategies

Answer Box: Your Next Steps When Zolgensma Is Denied

If Blue Cross Blue Shield North Carolina denies Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy, you have proven alternatives: Spinraza (nusinersen) and Evrysdi (risdiplam) are both FDA-approved, disease-modifying SMA treatments typically covered on BCBS formularies. First step: Request your neurologist submit a formulary exception with clinical documentation showing why alternatives won't work, or start with Spinraza/Evrysdi while building evidence for a future Zolgensma appeal. In North Carolina, denied patients can access free external review through Smart NC with 40-60% overturn rates for specialty drug appeals.

Table of Contents

When Alternatives Make Sense

Zolgensma denials often stem from age restrictions (typically limited to children under 2), missing genetic confirmation, or BCBS's preference for step therapy with proven alternatives. Rather than delay treatment, starting with formulary-covered options can provide immediate disease-modifying benefits while you build a stronger case for gene therapy.

Common BCBS denial reasons for Zolgensma:

  • Patient over 2 years old at time of request
  • No confirmatory genetic testing showing bi-allelic SMN1 mutations
  • Missing pre-treatment lab work (liver function, cardiac assessment)
  • Site of care limitations (requires specialized infusion center)
  • Step therapy requirements not met
Note: Both Spinraza and Evrysdi have shown significant clinical benefits in SMA patients and may be appropriate long-term treatments rather than just "bridge" therapies.

Typical SMA Treatment Alternatives

Coverage at a Glance

Treatment Route Age Range BCBS Formulary Status Key Requirements
Spinraza (nusinersen) Intrathecal injection All ages Preferred tier Genetic confirmation, neurologist prescription
Evrysdi (risdiplam) Oral daily ≥2 months Preferred tier Weight-based dosing, swallowing assessment
Zolgensma One-time IV <2 years (IV) Non-preferred/PA required Extensive pre-screening, specialized center

Spinraza (Nusinersen)

Mechanism: Antisense oligonucleotide that modifies SMN2 pre-mRNA splicing to increase functional SMN protein production.

Administration: Intrathecal (spinal) injection every 4 months after initial loading doses (days 0, 14, 28, and 63).

Clinical evidence: Proven efficacy across all SMA types in multiple randomized trials. Long-term data shows sustained motor function improvements and survival benefits.

BCBS coverage considerations:

  • Typically requires genetic confirmation of SMA
  • Must be prescribed by neurologist with SMA expertise
  • Cannot be used concurrently with other SMA treatments
  • Covered under medical benefit (not pharmacy)

Evrysdi (Risdiplam)

Mechanism: Small molecule SMN2 splicing modifier taken orally, increasing SMN protein levels throughout the body.

Administration: Daily oral solution with precise weight-based dosing:

  • <2 months: 0.15 mg/kg/day
  • 2 months-2 years: 0.2 mg/kg/day
  • 2+ years & <20kg: 0.25 mg/kg/day
  • 2+ years & ≥20kg: 5 mg/day

Clinical evidence: Indirect comparisons suggest superior survival outcomes versus Spinraza in Type 1 SMA, with convenient home administration.

BCBS coverage considerations:

  • Covered under pharmacy benefit
  • Requires prior authorization
  • Cannot combine with Spinraza or Zolgensma
  • May require feeding/swallowing assessment

Exception Strategy: When to Request Zolgensma

Building a Strong Formulary Exception Request

Even when alternatives are available, you may request a formulary exception for Zolgensma if clinical circumstances support it. Counterforce Health helps patients and clinicians turn insurance denials into targeted, evidence-backed appeals by analyzing denial letters and plan policies to craft point-by-point rebuttals aligned with payer requirements.

Key documentation for Zolgensma exception requests:

  1. Age justification: If over 2, provide evidence that earlier treatment wasn't available or appropriate
  2. Contraindications to alternatives: Document why Spinraza (lumbar puncture risks, coagulation issues) or Evrysdi (feeding difficulties, drug interactions) aren't suitable
  3. Clinical urgency: Rapid disease progression requiring one-time intervention
  4. Specialist support: Letter from SMA specialist explaining why gene therapy is medically necessary

Medical Necessity Letter Checklist

Your neurologist's exception request should include:

  • Diagnosis confirmation: ICD-10 codes, genetic testing results showing bi-allelic SMN1 mutations
  • SMA type and severity: Current functional status, rate of progression
  • Prior therapy considerations: Why alternatives failed, caused adverse effects, or are contraindicated
  • Treatment goals: Specific functional outcomes expected with Zolgensma
  • Supporting literature: FDA labeling, clinical trial data, specialty guidelines
Clinician Corner: Reference the FDA prescribing information and American Academy of Neurology practice parameters when building clinical rationale. Include baseline labs showing patient meets safety criteria.

Switching Between SMA Therapies

From Alternative to Zolgensma

Clinical evidence supports switching from Spinraza to Zolgensma in appropriate candidates, with case reports showing continued motor improvements and no unique safety concerns. Key considerations:

Timing: Allow 1-2 month washout between last Spinraza dose and Zolgensma infusion (no formal protocol established).

Monitoring: Enhanced surveillance for liver function, cardiac status, and immune response post-gene therapy.

Documentation: Track functional improvements or limitations with current therapy to support medical necessity for switching.

Coordination Requirements

Provider coordination:

  • Multidisciplinary team including neurologist, geneticist, and infusion center
  • Pre-authorization for new therapy before discontinuing current treatment
  • Transition planning to avoid treatment gaps

Pharmacy coordination:

  • Insurance notification of therapy change
  • Specialty pharmacy enrollment for new medication
  • Prior authorization transfer if switching benefit categories (medical vs. pharmacy)

Building Your Case for Future Zolgensma Appeals

Documentation Strategy During Alternative Therapy

While receiving Spinraza or Evrysdi, systematically document:

Functional assessments: Regular CHOP-INTEND, HINE-2, or age-appropriate motor scales Treatment burden: Time, travel, procedure complications for Spinraza; adherence challenges for Evrysdi Disease progression: Any continued decline despite treatment Quality of life impacts: Family burden, missed school/work, social limitations

When to Re-try Zolgensma

Consider resubmitting for Zolgensma when:

  • New clinical evidence emerges supporting efficacy in your situation
  • Alternative therapy shows limited benefit after adequate trial (typically 6-12 months)
  • Clinical status changes (e.g., feeding difficulties making Evrysdi less viable)
  • Plan formulary or coverage criteria change

North Carolina Appeals Process

Internal Appeals with BCBS

Level 1: Standard reconsideration (30 days) Level 2: Independent medical review within BCBS (30 days) Expedited: 72 hours for urgent cases

Submit appeals through BCBS member portal or provider portal with all supporting documentation.

External Review Through Smart NC

If BCBS upholds the denial after internal appeals, North Carolina residents can access free external review through Smart NC.

Key advantages:

  • Free to patients
  • Independent medical review by board-certified specialists
  • Binding decision - if overturned, BCBS must provide coverage
  • High success rates: 40-60% of specialty drug appeals are overturned with strong clinical documentation

Timeline:

  • Standard review: 45 days
  • Expedited review: 72 hours for urgent cases
  • Must request within 120 days of final internal denial

Contact Smart NC: 1-855-408-1212 for free guidance and advocacy support.

When navigating complex insurance denials, Counterforce Health provides specialized support by analyzing your specific denial letter and plan policy to identify the exact coverage criteria and draft targeted appeals that address each denial reason with appropriate clinical evidence.

FAQ

How long does BCBS prior authorization take for SMA treatments in North Carolina? Standard PA decisions take 5-15 business days. Expedited requests (for urgent medical need) receive decisions within 72 hours.

What if my child is over 2 but hasn't tried other SMA treatments? BCBS typically requires step therapy with age-appropriate alternatives (Spinraza or Evrysdi) before considering Zolgensma in older children, though exceptions may be granted with compelling clinical justification.

Can I switch from Evrysdi to Spinraza if the oral medication isn't working? Yes, switching between Spinraza and Evrysdi is clinically supported. Your neurologist will need to submit new prior authorization with documentation of inadequate response to current therapy.

Does step therapy apply if my child received SMA treatment in another state? Treatment history from other states should count toward step therapy requirements. Ensure your new provider has complete medical records showing prior therapies tried and outcomes.

What counts as "failure" of alternative therapy for exception requests? Lack of functional improvement after 6-12 months, continued disease progression, significant adverse effects, or inability to tolerate the treatment regimen.

How do I know if my BCBS plan is eligible for North Carolina external review? Most individual and small group plans are state-regulated and eligible. Large employer "self-funded" plans may not be covered unless they opted into North Carolina's system. Contact Smart NC at 1-855-408-1212 to verify eligibility.

From our advocates: We've seen families successfully obtain Zolgensma coverage after initial denials by carefully documenting why alternatives weren't suitable - for example, a toddler with severe scoliosis where repeated lumbar punctures for Spinraza posed surgical risks, or an infant with feeding difficulties making daily Evrysdi administration challenging. The key is building a compelling clinical narrative that addresses the plan's specific coverage criteria.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage policies vary by plan and change frequently. Always consult with your healthcare provider and insurance plan directly for the most current coverage information and medical guidance appropriate for your situation.

Sources & Further Reading:

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.